Loading clinical trials...

RECRUITINGPHASE2

Venetoclax Combined With Azactidine in the Treatment of ALAL

A Multicenter Prospective Clinical Study of Venetoclax Combined With Azactidine in the Treatment of Acute Leukaemias of Ambiguous Lineage

NCT05901974•Sheng-Li Xue, MD

View on ClinicalTrials.gov

Summary

The prognosis of acute leukaemias of ambiguous lineage is poor. The effect of chemotherapy regimen and hematopoietic stem cell transplantation are still unclear. Therefore, we will explore new therapy to improve the remission rate of acute leukaemias of ambiguous lineage. Venetoclax can significantly improve the remission rate and prolong PFS and OS. At present, venetoclax combined with azacitidine or decitabine has become the preferred treatment regimen for elderly AML patients. It also shows a high response rate in relapsed/refractory AML or MDS patients. There are few clinical studies on the treatment of ALAL. The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine in the treatment of newly diagnosed ALAL patients.

Eligibility

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients aged ≥ 15 years.
•2. Patients diagnosed with ALAL according to 5th edition of WHO Acute Leukaemias of Ambiguous Lineage diagnosis standard.
•3. New diagnosed patients.
•4. ECOG performance status score less than 3.
•5. Expected survival time ≥3 months.
•6. Patients without serious heart, lung, liver, or kidney disease.
•7. Ability to understand and voluntarily provide informed consent.

Exclusion Criteria

•1. Patients who are allergic to the study drug or drugs with similar chemical structures.
•2. Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception.
•3. Active infection.
•4. Active bleeding.
•5. Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment.
•6. Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met.
•7. Liver function abnormalities (total bilirubin \> 1.5 times the upper limit of the normal range, ALT/AST \> 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST \> 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine \> 1.5 times the upper limit of the normal value).
•8. Patients with a history of clinically significant QTc interval prolongation (male \> 450 ms; female \> 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment.
•9. Surgery on the main organs within the past six weeks.
•10. Drug abuse or long-term alcohol abuse that would affect the evaluation results.
+2 more criteria

Locations (1)

The First Affliated Hospital of Soochow University

Suzhou, China

Key Dates

Start Date

July 1, 2023

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

December 16, 2025

Enrollment

ESTIMATED participants

Conditions

Acute Leukemia of Ambiguous Lineage

Interventions

Venetoclax

DRUG

azactidine

DRUG

Contacts

Sheng-Li Xue, MD

CONTACT

0086-0512-67781139 slxue@suda.edu.cn

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399

Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia+3 more

View study

RECRUITINGPHASE1

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT05292664

Myelodysplastic Syndromes, de NovoMyelodysplastic Syndromes, Secondary+9 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 16, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Venetoclax Combined With Azactidine in the Treatment of ALAL

Inclusion Criteria

Exclusion Criteria

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia